{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T10:40:47Z","timestamp":1771670447125,"version":"3.50.1"},"reference-count":71,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,3,16]],"date-time":"2023-03-16T00:00:00Z","timestamp":1678924800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Primary squamous cell carcinoma of the thyroid (PSCCT) is a rare malignant tumor. The incidence rate of PSCCT is less than 1%. However, the diagnosis and treatment of PSCCT are limited. Surgical resection is considered to be one of the few effective intervention methods. In this article, we reported a case of taking tyrosine kinase inhibitors (TKIs) combined with immune checkpoint inhibitors (ICIs) for PSCCT.<\/jats:p><\/jats:sec><jats:sec><jats:title>Case summary<\/jats:title><jats:p>An 80-year-old male was admitted to our hospital with dyspnea, cough, wheezing, and hoarseness for a giant thyroid mass. He underwent bronchoscopy and tracheal stent implantation to alleviate the respiratory obstruction. Then he accepted right partial thyroid and right lymph node biopsy. Postoperative pathology revealed squamous cell carcinoma. Subsequently, he underwent an endoscopy to exclude upper gastrointestinal squamous cell carcinoma. Finally, he was diagnosed with PSCCT. The patient was tentatively treated with a combination of Anlotinib and Sintilimab. After two courses, the tumor volume significantly reduced in MRI images and shrank further after five courses of combined treatment. Unfortunately, the patient died of fulminant liver failure and autoimmune liver disease after 5-month-treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>TKIs combined with ICIs may be an effective and novel way for PSCCT treatment, but immune-related complications, especially liver damage, should be cared.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2023.976415","type":"journal-article","created":{"date-parts":[[2023,3,16]],"date-time":"2023-03-16T17:02:57Z","timestamp":1678986177000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Anlotinib combined with Sintilimab is win-win cooperation for primary squamous cell carcinoma of the thyroid: A case report and literature review"],"prefix":"10.3389","volume":"13","author":[{"given":"Zichang","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maosheng","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feng","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chenfang","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,3,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1089\/thy.2006.16.89","article-title":"Primary squamous cell carcinoma of the thyroid: report of ten cases","volume":"16","author":"Booya","year":"2006","journal-title":"Thyroid"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1053\/ejso.1999.0715","article-title":"Squamous cell carcinoma of the thyroid: outcome of treatment in 16 patients","volume":"25","author":"Cook","year":"1999","journal-title":"Eur J Surg Oncol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.ijscr.2017.06.011","article-title":"Primary squamous cell carcinoma of the thyroid: Case report and systematic review of the literature","volume":"37","author":"Struller","year":"2017","journal-title":"Int J Surg Case Rep"},{"key":"B4","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1017\/S0022215110002070","article-title":"Squamous cell carcinoma of the thyroid gland: primary or secondary disease","volume":"125","author":"Syed","year":"2011","journal-title":"J Laryngol Otol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1177\/0194599817698436","article-title":"Primary squamous cell carcinoma of the thyroid: A population-based analysis","volume":"157","author":"Au","year":"2017","journal-title":"Otolaryngol Head Neck Surg"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-20-0045","article-title":"Squamous cell carcinoma of thyroid: a unique type of cancer in world health organization classification","volume":"27","author":"Lam","year":"2020","journal-title":"Endocr Relat Cancer"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/s00268-019-04906-2","article-title":"Primary squamous cell carcinoma in the thyroid gland: A population-based analysis using the SEER database","volume":"43","author":"Yang","year":"2019","journal-title":"World J Surg"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1002\/hed.23152","article-title":"Primary squamous cell carcinoma of the thyroid gland: a case report and review","volume":"35","author":"Shrestha","year":"2013","journal-title":"Head Neck"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.21037\/gs-20-628","article-title":"Analysis of primary and secondary squamous cell carcinoma of the thyroid gland: a retrospective study","volume":"10","author":"Liu","year":"2021","journal-title":"Gland Surg"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.21037\/gs.2019.11.07","article-title":"Treatment optimization and prognostic considerations for primary squamous cell carcinoma of the thyroid","volume":"8","author":"Wang","year":"2019","journal-title":"Gland Surg"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1002\/dc.10178","article-title":"Primary squamous-cell carcinoma of the thyroid gland: new evidence in support of follicular epithelial cell origin","volume":"27","author":"Sahoo","year":"2002","journal-title":"Diagn Cytopathol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2559.2001.01207.x","article-title":"Primary squamous cell carcinoma of the thyroid gland: an entity with aggressive clinical behaviour and distinctive cytokeratin expression profiles","volume":"39","author":"Lam","year":"2001","journal-title":"Histopathology"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2011.173","article-title":"p40 (\u0394Np63) is superior to p63 for the diagnosis of pulmonary squamous cell carcinoma","volume":"25","author":"Bishop","year":"2012","journal-title":"Mod Pathol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1309\/21TW-2NDG-JRK4-PFJX","article-title":"Value of p63 and cytokeratin 5\/6 as immunohistochemical markers for the differential diagnosis of poorly differentiated and undifferentiated carcinomas","volume":"116","author":"Kaufmann","year":"2001","journal-title":"Am J Clin Pathol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1159\/000518055","article-title":"Therapeutic effect of combined dabrafenib and trametinib treatment of BRAF V600E-mutated primary squamous cell carcinoma of the thyroid: A case report","volume":"10","author":"Brandenburg","year":"2021","journal-title":"Eur Thyroid J"},{"key":"B16","doi-asserted-by":"publisher","first-page":"3000605211004702","DOI":"10.1177\/03000605211004702","article-title":"Primary squamous cell carcinoma of the thyroid: a case report","volume":"49","author":"Xin","year":"2021","journal-title":"J Int Med Res"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.21037\/gs.2020.02.18","article-title":"Primary squamous cell carcinoma (PSCC) of the thyroid: a case report and review of the literature","volume":"9","author":"Sun","year":"2020","journal-title":"Gland Surg"},{"key":"B18","doi-asserted-by":"publisher","first-page":"153146","DOI":"10.1016\/j.prp.2020.153146","article-title":"Primary squamous cell carcinoma of thyroid with a novel BRAF mutation and high PDL-1 expression: A case report with treatment implications and review of literature","volume":"216","author":"Torrez","year":"2020","journal-title":"Pathol Res Pract"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.31486\/toj.18.0002","article-title":"Primary squamous cell carcinoma of the thyroid","volume":"19","author":"Raggio","year":"2019","journal-title":"Ochsner J"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.7417\/CT.2019.2138","article-title":"Total thyroidectomy associated to chemotherapy in primary squamous cell carcinoma of the thyroid","volume":"170","author":"De Cesare","year":"2019","journal-title":"Clin Ter"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.anl.2017.07.009","article-title":"The treatment and outcome analysis of primary squamous cell carcinoma of the thyroid","volume":"45","author":"Yasumatsu","year":"2018","journal-title":"Auris Nasus Larynx"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.3190","article-title":"Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer","volume":"309","author":"Xing","year":"2013","journal-title":"JAMA"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.beem.2008.09.017","article-title":"Molecular pathology of thyroid cancer: diagnostic and clinical implications","volume":"22","author":"Fagin","year":"2008","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)60109-9","article-title":"Progress in molecular-based management of differentiated thyroid cancer","volume":"381","author":"Xing","year":"2013","journal-title":"Lancet"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2011.141","article-title":"Multikinase inhibitors: a new option for the treatment of thyroid cancer","volume":"7","author":"Gild","year":"2011","journal-title":"Nat Rev Endocrinol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2018.03.035","article-title":"Oncogenic signaling pathways in the cancer genome atlas","volume":"173","author":"Sanchez-Vega","year":"2018","journal-title":"Cell"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3390\/cancers7030860","article-title":"Targeting RTK signaling pathways in cancer","volume":"7","author":"Regad","year":"2015","journal-title":"Cancers (Basel)"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/nrd.2018.21","article-title":"Kinase inhibitors: the road ahead","volume":"17","author":"Ferguson","year":"2018","journal-title":"Nat Rev Drug Discovery"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-020-00465-y","article-title":"Multikinase inhibitors in thyroid cancer: timing of targeted therapy","volume":"17","author":"Gild","year":"2021","journal-title":"Nat Rev Endocrinol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mds230","article-title":"Thyroid cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","author":"Pacini","year":"2012","journal-title":"Ann Oncol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s13045-018-0664-7","article-title":"Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development","volume":"11","author":"Shen","year":"2018","journal-title":"J Hematol Oncol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s13045-016-0332-8","article-title":"Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors","volume":"9","author":"Sun","year":"2016","journal-title":"J Hematol Oncol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s40880-019-0383-7","article-title":"China National medical products administration approval summary: anlotinib for the treatment of advanced non-small cell lung cancer after two lines of chemotherapy","volume":"39","author":"Zhou","year":"2019","journal-title":"Cancer Commun (Lond)"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-17-0558","article-title":"Antitumor effects of anlotinib in thyroid cancer","volume":"26","author":"Ruan","year":"2019","journal-title":"Endocr Relat Cancer"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-2950","article-title":"Anlotinib in locally advanced or metastatic medullary thyroid carcinoma: A randomized, double-blind phase IIB trial","volume":"27","author":"Li","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B36","doi-asserted-by":"publisher","first-page":"86","DOI":"10.3322\/caac.21596","article-title":"A review of cancer immunotherapy toxicity","volume":"70","author":"Kennedy","year":"2020","journal-title":"CA Cancer J Clin"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-004-0593-x","article-title":"Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy","volume":"54","author":"Blank","year":"2005","journal-title":"Cancer Immunol Immunother"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.192461099","article-title":"Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade","volume":"99","author":"Iwai","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.7150\/thno.50333","article-title":"From biomarkers to therapeutic targets: the promise of PD-L1 in thyroid autoimmunity and cancer","volume":"11","author":"D'Andr\u00e9a","year":"2021","journal-title":"Theranostics"},{"key":"B40","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s12943-021-01489-2","article-title":"Combination strategies with PD-1\/PD-L1 blockade: current advances and future directions","volume":"21","author":"Yi","year":"2022","journal-title":"Mol Cancer"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pathol-042020-042741","article-title":"Immune checkpoint inhibitors for the treatment of cancer: Clinical impact and mechanisms of response and resistance","volume":"16","author":"Bagchi","year":"2021","journal-title":"Annu Rev Pathol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1186\/s12885-019-5380-3","article-title":"Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced, PD-L1-positive papillary or follicular thyroid cancer","volume":"19","author":"Mehnert","year":"2019","journal-title":"BMC Cancer"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-019-1066-z","article-title":"Sintilimab: First global approval","volume":"79","author":"Hoy","year":"2019","journal-title":"Drugs"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(18)30192-3","article-title":"Safety and activity of sintilimab in patients with relapsed or refractory classical Hodgkin lymphoma (ORIENT-1): a multicentre, single-arm, phase 2 trial","volume":"6","author":"Shi","year":"2019","journal-title":"Lancet Haematol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s40364-020-00250-z","article-title":"Recent updates on sintilimab in solid tumor immunotherapy","volume":"8","author":"Liu","year":"2020","journal-title":"biomark Res"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2021-068714","article-title":"Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (ORIENT-15): multicentre, randomised, double blind, phase 3 trial","volume":"377","author":"Lu","year":"2022","journal-title":"BMJ"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.cn112151-20210228-00172","article-title":"[Consensus on the immunohistochemical tests of PD-L1 in solid tumors (2021 version)]","volume":"50","author":"Lin","year":"2021","journal-title":"Zhonghua Bing Li Xue Za Zhi"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01234-4","article-title":"Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study","volume":"398","author":"Sun","year":"2021","journal-title":"Lancet"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-1543","article-title":"The intersection between tumor angiogenesis and immune suppression","volume":"25","author":"Rahma","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B50","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.jtho.2016.10.003","article-title":"The potential of combined immunotherapy and antiangiogenesis for the synergistic treatment of advanced NSCLC","volume":"12","author":"Manegold","year":"2017","journal-title":"J Thorac Oncol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2018.9","article-title":"Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa","volume":"15","author":"Khan","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1385\/IR:23:2-3:263","article-title":"VEGF as a mediator of tumor-associated immunodeficiency","volume":"23","author":"Ohm","year":"2001","journal-title":"Immunol Res"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1038\/nm1096-1096","article-title":"Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells","volume":"2","author":"Gabrilovich","year":"1996","journal-title":"Nat Med"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V92.11.4150","article-title":"Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo","volume":"92","author":"Gabrilovich","year":"1998","journal-title":"Blood"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.178.3.1505","article-title":"Effects of vascular endothelial growth factor on the lymphocyte-endothelium interactions: identification of caveolin-1 and nitric oxide as control points of endothelial cell anergy","volume":"178","author":"Bouzin","year":"2007","journal-title":"J Immunol"},{"key":"B56","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1038\/s41419-020-2511-3","article-title":"Anlotinib alters tumor immune microenvironment by downregulating PD-L1 expression on vascular endothelial cells","volume":"11","author":"Liu","year":"2020","journal-title":"Cell Death Dis"},{"key":"B57","article-title":"A critical requirement of interferon gamma-mediated angiostasis for tumor rejection by CD8+ T cells","volume":"63","author":"Qin","year":"2003","journal-title":"Cancer Res"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1002\/path.4340","article-title":"IFN\u03b3-responsiveness of endothelial cells leads to efficient angiostasis in tumours involving down-regulation of Dll4","volume":"233","author":"Deng","year":"2014","journal-title":"J Pathol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0901073","article-title":"Responsiveness of stromal fibroblasts to IFN-gamma blocks tumor growth via angiostasis","volume":"183","author":"Lu","year":"2009","journal-title":"J Immunol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1816714","article-title":"Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Rini","year":"2019","journal-title":"N Engl J Med"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0053-3","article-title":"Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma","volume":"24","author":"McDermott","year":"2018","journal-title":"Nat Med"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30458-9","article-title":"Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a\/b trial","volume":"20","author":"Herbst","year":"2019","journal-title":"Lancet Oncol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.02627","article-title":"Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer","volume":"38","author":"Makker","year":"2020","journal-title":"J Clin Oncol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.01598","article-title":"Phase IB\/II trial of lenvatinib plus pembrolizumab in patients with advanced renal cell carcinoma, endometrial cancer, and other selected advanced solid tumors","volume":"38","author":"Taylor","year":"2020","journal-title":"J Clin Oncol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-021-02869-9","article-title":"Anlotinib combined with PD-1 blockade for the treatment of lung cancer: a real-world retrospective study in China","volume":"70","author":"Zhang","year":"2021","journal-title":"Cancer Immunol Immunother"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2020.11.026","article-title":"Phase 1b study of sintilimab plus anlotinib as first-line therapy in patients with advanced NSCLC","volume":"16","author":"Chu","year":"2021","journal-title":"J Thorac Oncol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2015.11.016","article-title":"Immune-related adverse events with immune checkpoint blockade: a comprehensive review","volume":"54","author":"Michot","year":"2016","journal-title":"Eur J Cancer"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2015.33.15_suppl.9018","article-title":"Safety profile of nivolumab (NIVO) in patients (pts) with advanced melanoma (MEL): A pooled analysis","volume":"33","author":"Weber","year":"2015","journal-title":"J Clin Oncol"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.27969","article-title":"Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab: detailed safety analysis from a phase 3 trial in patients with advanced melanoma","volume":"119","author":"Weber","year":"2013","journal-title":"Cancer"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-013-9939-6","article-title":"Ipilimumab associated hepatitis: imaging and clinicopathologic findings","volume":"31","author":"Kim","year":"2013","journal-title":"Invest New Drugs"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.976415\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,16]],"date-time":"2023-03-16T17:03:02Z","timestamp":1678986182000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.976415\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,16]]},"references-count":71,"alternative-id":["10.3389\/fonc.2023.976415"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2023.976415","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,16]]},"article-number":"976415"}}